


PERSONAL INFORMATION **Gina MANDA**



 www.ivb.ro

WORK
EXPERIENCE

1993 - onwards „Victor Babes” National Institute of Pathology, 99-101 Splaiul Independentei, 050096 Bucharest, Romania

- Scientific researcher grade I (since 2016)
- Head of Radiobiology Laboratory (2009-2023, 2024-)
- Head of the Nuclear Unit (since 2014)
- Member of the Scientific Council (since 2009)
- Scientific secretary (2009-2013)
- Responsible with QA in research (2009-2013)

Former scientific positions:

- Scientific researcher grade II (1999-2016)
- Scientific researcher grade III (1996-1999)
- Research assistant (1993-1996)

▪ Coordinator of research projects in the field of radiobiology, preclinical screening of drugs, immunology, neurosciences

Type of sector: biomedical research

1987 - 1993

Research assistant
PhD student (1990-1996)

„Ion Cantacuzino” Institute, 103 Splaiul Independentei, Bucharest, Romania

▪ team member in research projects in the field of immunology and immunomodulation
Type of sector: biomedical research

1986 - 1988

Research assistant

Institute for Energetic Nuclear Power Plants, Mioveni, Jud. Ages, Romania

▪ dosimetry

Type of sector: nuclear research

EDUCATION AND TRAINING

- 1990 - 1996 **PhD**
 Faculty of Physics, University of Bucharest, Romania
- Biophysics: biology of reactive oxygen species in health and disease
- 1992 **Specialization in autoimmunity**
 INSERM U354, Paris, France (Prof. Raymond Frade). Specialization in autoimmunity - the idiotype network of the complement receptor CR1 in rheumatoid arthritis
- 1984 - 1985 **Master**
 Faculty of Physics, University of Bucharest, Romania
- Polymer physics: electrical properties of liquid crystals
- 1980 - 1984 **Bachelor in physics**
 Faculty of Physics, University of Bucharest, Romania
- Physics

PERSONAL SKILLS

| | | | | | |
|--|---------------|---------|--------------------|-------------------|---------|
| Mother tongue(s) | Romanian | | | | |
| Other language(s) | UNDERSTANDING | | SPEAKING | | WRITING |
| | Listening | Reading | Spoken interaction | Spoken production | |
| English | C2 | C2 | C2 | C2 | C2 |
| Replace with name of language certificate. Enter level if known. | | | | | |
| French | C2 | C2 | B2 | B2 | B2 |

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
[Common European Framework of Reference for Languages](#)

Communication skills Excellent scientific communication gained in multi-disciplinary research projects, both national and international (more than 100 oral communications). Excellent communication as trainer gained in European training projects having as target groups medical doctors working in the Romanian health system or PhD students in the biomedical field.

Organisational / managerial skills **“Victor Babes” National Institute of Pathology, Bucharest, Romania**
2003-2013: Responsible for quality management in research (~60 researchers)
2009-2013: Scientific secretary of the institute (~60 researchers)
2009-2023 Head of Radiobiology Laboratory (5-11 researchers)
2009-2019 Coordinator of the functional team Drug development and (immune)toxicology (~18 researchers)
2009 – until now, Member of the Scientific Council of Victor Babes National Institute

Job-related skills Technical expertise

- excellent command of cell cultures and functional cellular tests
- excellent command of radiobiologic techniques with radiolabelled biomolecules
- good command of flow cytometry and ELISA

Digital competence

| SELF-ASSESSMENT | | | | |
|------------------------|---------------|------------------|--------|-----------------|
| Information processing | Communication | Content creation | Safety | Problem solving |

| | | | | |
|-----------------|-----------------|-----------------|------------|------------|
| Proficient user | Proficient user | Proficient user | Basic user | Basic user |
|-----------------|-----------------|-----------------|------------|------------|

Levels: Basic user - Independent user - Proficient user

[Digital competences - Self-assessment grid](#)

- good command of office suite (word processor, spread sheet, presentation software)
- good command of statistical processing of biomedical data.

ADDITIONAL INFORMATION

| | |
|----------------------|---|
| H-Index | H-Index = 24 (Google Scholar); H-Index = 23 (Scopus) |
| Publications | >160 publications (Google Scholar). 113 ISI-indexed publications See the appended List of selected publications |
| Citations | 3760 Google Scholar citations (2830 since 2019), 1817 ISI Web of knowledge citations (without sel-citations) |
| Project coordination | Project coordinator of 13 scientific projects (3 international and 10 national projects) and project co-director in 12 scientific projects, member of the management team in 2 COST Actions (WG vice-leader in one project, Vice-chair and Scientific representative of the Grant Holder in the 2nd COST Action) in one of these projects) and a management position in two European projects dedicated to Romania for training |
| Evaluator | Evaluator at national research projects calls Evaluator for the COST programme since 2014 Evaluator for the following journals: Journal of Cellular and Molecular Medicine, International Journal of Molecular Sciences, Oxidative Medicine and Cellular Longevity, British Journal of Cancer, Toxins, Journal of Neurology & Neuromedicine, Journal of Mental Health and Clinical Psychology, Molecular Life, Biophysical Reviews, Colloids and Surfaces B: Biointerfaces, Beilstein, Cell |
| Management courses | 2007 Development of projects financed from European and international funds, Predeal, Romania 2007 Training of Assessors for „IPMA Model for Project Excellence”, Bucharest, Romania 2017 Technology transfer course, Bucharest, Romania 2019 Radiologic security for practices with ionizing radiation sources, Magurele, Romania |

ANNEXES

- List of selected publications (books and scientific articles)
- List of patents
- List of selected projects

31.07.2024

Gina MANDA

List of publications (selection)

BOOKS

1. **Methotrexate liposomes – a reliable therapeutic option.** Ciobanu AM, Barca M, Manda G, Burcea GTA. Chapter 10, page 171, in *Liposomes*, Catala A, Ed, InTech Open, 2017. ISBN: 978-953-51-3580-7
2. **Guide for the organization of the immunology laboratory.** Prof. Dr. Victor Cristea, coordinator. Auhors (in alphabetical order): Cornelia Braicu, Ioana Berindan-Neagoe, Roxana Cojocneanu-Petric, Carolina Constantin, Maria Dobre, Radu-Ionut Huică, Laura Ispravă, Gina Manda, Ionela Neagoe, Monica Neagu, Aurora Sălăgeanu, Mihaela Surcel, Cătălin Tucureanu, Cornel Ursaciuc, Mihaela Zlei. Editura Medicală Universitară "Iuliu Hațieganu", Cluj-Napoca, 2013. ISBN 978-973-693-550-3.
3. **Medical spectrometry manual.** Coordinator Prof. Dr. Mihail Eugen Hinescu. Authors Florin Mitu, Gina Manda, Vasile Preoteasa, Daniela Baconi, Ionela Neagoe. Editura Viata Medicala Romaneasca, Bucuresti, 2013. ISBN 978-973-160-074-1.
4. **Fundamental immunology.** Cornel Ursaciuc, Monica Neagu, Gina Manda. "Viata Medicala Romaneasca" Publishing House, 164 pgs., 2012.
5. **Trends in Interdisciplinary Studies Revealing Porphyrinic Compounds Multivalency Towards Biomedical Application.** Socoteanu Radu, Rica Boscencu, Anca Hirtopeanu, Gina Manda, Anabela Sousa Oliveira, Mihaela Ilie, Luis Filipe Vieira Ferreira, in *Biomedical Engineering – From Theory to Applications*, Reza Fazel-Rezai Ed, InTech Publishing House, p. 355-390, 2011, ISBN 978-953-307-637-9.
6. **Methods of Humoral and Cellular Immunology.** Dorel L. Radu, Crina Stavaru, Iuliana Caras, Gina Manda, Monica Neagu, Eugen Radu, Cornel Ursaciuc, Laurentiu Mircea Popescu, University Publishing House "Carol Davila", Bucharest, 2006, ISBN: 973-708-084-X
7. **Interferences at the respiratory burst level between the signals delivered *in vitro* to human peripheral neutrophils via fMLP, complement and Fc receptors.** Marinela Bostan, Alexandra Livescu, Monica Neagu, Gina Manda, Maria Chirilă, Elena Mazălu, A. C. Bancu, L.M. Popescu. In *Immunoregulation in Health and Disease, Experimental and Clinical Aspects*, M.L. Lukic, M. Colic, Marija Mostarica-Stojkovic and K. Cuperlovic Eds, Academic Press, Section 4: Host reactivity to graft, tumor and infection, Chapter 41, p. 431-438, 1997.

SELECTED SCIENTIFIC ARTICLES

1. AM Burloiu, G Manda*, D Lupuliasa, RP Socoteanu, DP Mihai, IV Neagoe, LI Anghelache, M Surcel, M Anastasescu, L Olariu, CE Gird, SF Barbuceanu, LFV Ferreira, R Boscencu. **Assessment of Some Unsymmetrical Porphyrins as Promising Molecules for Photodynamic Therapy of Cutaneous Disorders.** *Pharmaceuticals* 2024, 17, 62. <https://doi.org/10.3390/ph17010062>. IF 4.6
2. A Gkikoudi, SA Kalospyros, S Triantopoulou, S Logotheti, V Softa, C Kappas, K Theodorou, EC Laiakis, G Manda, GI Terzoudi, AG Georgakilas. **Molecular Biomarkers for Predicting Cancer Patient Radiosensitivity and Radiotoxicity in Clinical Practice.** *Appl. Sci.* 2023, 13(23), 12564; <https://doi.org/10.3390/app132312564>. IF 2.7
3. A Ciobanu, G Manda, I Neagoe, M Barca, C Balalau, EG Turcu, CM Gutu, DE Popa, DL Baconi. **The immune status of heroin addicts during treatment with methadone.** *Farmacia* 71 (6), 2023, <https://doi.org/10.31925/farmacia.2023.6.9>. IF 1.6
4. R Boscencu, G Manda, G Vasiliu, R Socoteanu, D Lupuleasa, AM Burloiu, IV Neagoe, L Olariu. **Preliminary In Vitro Evaluation of Some Porphyrins Using Human Breast Tumor Cells.** *Letters in Drug Design & Discovery*, 20 (8), 1040-1045, DOI:10.2174/1570180819666220318153003. IF 1.099
5. Radu M Serban, Dana Niculae*, Gina Manda*, Ionela Neagoe, Maria Dobre, Dragoș A Niculae, Mihaela Temelie, Cosmin Mustăciosu, Radu A Leonte, Livia E Chilug, Maria R Cornoiu, Diana Cocioabă, Miruna Stan, Anca Dinischiotu. **Modifications in cellular viability, DNA damage**

- and stress responses inflicted in cancer cells by copper-64 ions.** *Frontiers in Medicine*, 10: 1197846, 2023, <https://doi.org/10.3389/fmed.2023.1197846>. IF 9.927
6. Dragos Paul Mihai, Rica Boscencu, Gina Manda, Andreea Mihaela Burloiu, Georgiana Vasiliu, Ionela Victoria Neagoe, Radu Petre Socoteanu, Dumitru Lupuliasa. **Interaction of Some Asymmetrical Porphyrins with U937 Cell Membranes–In Vitro and In Silico Studies.** *Molecules*, 28(4): 1640, 2023. <https://doi.org/10.3390/molecules28041640>. IF 4.6
 7. R Boscencu, N Radulea, G Manda, IF Machado, RP Socoteanu, D Lupuliasa, AM Burloiu, DP Mihai, LF Vieira Ferreira. **Porphyrin Macrocycles: General Properties and Theranostic Potential.** *Molecules* 2023, 28, 1149. <https://doi.org/10.3390/molecules28031149>. IF 4.6
 8. Suniti Bhaumik, Marzena Łazarczyk, Norwin Kubick, Pavel Klimovich, Agata Gurba, Justyna Paszkiewicz, Patrycja Teodorowicz, Tomasz Kocki, Jarosław Olav Horbańczuk, Gina Manda, Mariusz Sacharczuk, Michel-Edwar Mickael. **Investigation of the Molecular Evolution of Treg Suppression Mechanisms Indicates a Convergent Origin.** *Current Issues in Molecular Biology*, 3: 628-648, 2023, <https://doi.org/10.3390/cimb45010042>. IF 2.976
 9. Gina Manda, Elena Milanese, Sermin Genc, Cristina Mariana Niculite, Ionela Victoria Neagoe, Bora Tastan, Elena Mihaela Dragnea, Antonio Cuadrado*. **Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis.** *Free Radical Biology and Medicine*, 190: 179-201, 2022. IF 7.4
 10. Milanese E, Dobre M, Cucos CA, Rojo AI, Jiménez-Villegas J, Capetillo-Zarate E, Matute C, Piñol-Ripoll G, Manda G*, Cuadrado A*. **Whole blood expression pattern of inflammation and redox genes in mild cognitive impairment.** *Journal of Inflammation Research*, Volume 2021, 14: 6085—6102, doi: 10.2147/JIR.S334337. IF 6.532.
 11. Milanese E, Cucos CA, Matias-Guiu JA, Piñol-Ripoll G, Manda G, Dobre M, Cuadrado A. **Reduced blood RGS2 expression in mild cognitive impairment patients.** *Frontiers in Aging Neuroscience*, 29 September 2021, doi: 10.3389/fnagi.2021.738244. IF 5.750.
 12. Cucos CA, Cracana I, Dobre M, Surcel M, Popescu BO, Tudose C, Spiru L, Manda G, Niculescu G, Milanese E. **Sulfiredoxin-1 blood mRNA expression levels negatively correlate with hippocampal atrophy and cognitive decline.** *F1000Res*. 2022 Jan 28; 11:114. doi: 10.12688/f1000research.76191.2. IF 2.297.
 13. Cucos CA, Dobre M, Dragnea EM, Manda G, Milanese E. **Increased MYD88 blood transcript in a mouse model of Alzheimer's disease.** *BMC Neurosci*. 2022 Mar 11; 23(1):13. doi: 10.1186/s12868-022-00699-8. IF 3.288.
 14. Cucos CA, Milanese E, Dobre M, Musat IA, Manda G*, Cuadrado A*. **Altered Blood and Brain Expression of Inflammation and Redox Genes in Alzheimer's Disease, Common to APPV717I × TAUP301L Mice and Patients;** *Int J Mol Sci*. 2022 May 21;23(10):5799. doi: 10.3390/ijms23105799. IF 5.542.
 15. Dobre, Maria, Rica Boscencu, Ionela V. Neagoe, Mihaela Surcel, Elena Milanese, and Gina Manda. 2021. **Insight into the Web of Stress Responses Triggered at Gene Expression Level by Porphyrin-PDT in HT29 Human Colon Carcinoma Cells,** *Pharmaceutics* 2021, 13(7): 1032. <https://doi.org/10.3390/pharmaceutics13071032>. IF=6.23
 16. Radu Anton Leonte, Livia Elena Chilug, Radu Șerban, Cosmin Mustăciosu, Alina Raicu, Gina Manda, Dana Niculae. **Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with 68Ga and 177Lu as Potential Theranostic Agent for Colon Cancer.** *Pharmaceutics* 2021, 13(4): 506. IF=6.23
 17. Radu Petre Socoteanu, Rica Boscencu, Gina Manda, Mihai Anastasescu, Ionela Victoria Neagoe, Isabel Ferreira Machado, Octavian Dinca, Alexandru Bucur, Luis Filipe Vieira Ferreira. **Morphologic evaluation of some promising A3B porphyrinic type compounds designed for theranostic applications in cancer.** *Chemical Physics* 2021, 544: 11115. IF= 1.707
 18. Elena Milanese, Gina Manda, Maria Dobre, Elena Codrici, Ionela Victoria Neagoe, Bogdan Ovidiu Popescu, Ovidiu Alexandru Bajenaru, Luiza Spiru, Catalina Tudose, Gabriel-Ioan Prada, Eugenia Irene Davidescu, Gerard Piñol-Ripoll, Antonio Cuadrado. **Distinctive under-expression profile of inflammatory and redox genes in the blood of elderly patients with cardiovascular disease.** *Journal of Inflammation Research* 2021, 14: 429. IF=4.953

19. Norwin Kubick, Patrick C Henckell Flournoy, Ana-Maria Enciu, Gina Manda, Michel-Edwar Mickael. **Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’s Disease.** *Pharmaceutics*, 12(9), 880, 2020. **IF = 4.421**
20. Norwin Kubick, Patrick C. Henckell Flournoy, Pavel Klimovich, Gina Manda, Michel-Edwar Mickael. **What has single-cell RNA sequencing revealed about microglial neuroimmunology?** *Immunology, Inflammation and Disease* 2020, <https://doi.org/10.1002/iid3.362>. **IF= 2.5**
21. Gina Manda, Antonio Cuadrado, **The transcription factor NRF2 shapes the identity of radio-resistant tumor cells.** *Journal of Cell Identity* 2020, 1: 49–81;DOI: 10.47570/joci.2020.004).
22. Livia Elena Chilug, Dana Niculae, Radu Anton Leonte, Alexandrina Nan, Rodica Turcu, Cosmin Mustaciosu, Radu Marian Serban, Vasile Lavric, Gina Manda. **Preclinical Evaluation of NHS-Activated Gold Nanoparticles Functionalized with Bombesin or Neurotensin-Like Peptides for Targeting Colon and Prostate Tumours.** *Molecules* 2020, 25: 3363. **IF = 3.267**
23. Antonio Cuadrado, Marta Pajares, Cristina Benito, José Jiménez-Villegas, Maribel Escoll, Raquel Fernández-Ginés, Angel J. Garcia Yagüe, Diego Lastra, Gina Manda, Ana I. Rojo, Albena T. Dinkova-Kostova. **Can Activation of NRF2 Be a Strategy against COVID-19?** *Trends in Pharmacological Sciences*, 1738, 22 July 2020. **IF = 11.523**
24. Marta Pajares, Ana I. Rojo, Gina Manda, Lisardo Boscá, Antonio Cuadrado. **Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications.** *Cells* 2020, 9(7), 1687. **IF = 4.366**
25. Norwin Kubick, Marta Pajares, Ioana Enache, Gina Manda, Michel-Edwar Mickael. **Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach.** *Molecules* 2020, 25(9): 2155. **IF = 3.267**
26. Gina Manda, Cristian Postolache, Ionela Victoria Neagoe, Andreea Csolti, Elena Milanesi, Maria Dobre. **The expression profile of redox genes in human monocytes exposed *in vitro* to γ radiation.** *Radiation Physics and Chemistry* 2019, 170: 108634. **IF =1.435**
27. Gina Manda, Ana I. Rojo, Elena Martínez-Klimova , José Pedraza-Chaverri, Antonio Cuadrado. **Nordihydroguaiaretic acid: from herbal medicine to clinical development for cancer and chronic diseases.** *Frontiers Pharmacology* 2019, 11:151. **IF = 3.845**
28. Alina-Andreea Zimta, Vlad Schitcu, Eugen Gurzau, Crina Stavaru, Gina Manda, Stefan Szedlacsek, Ioana Berindan-Neagoe. **Biological and molecular modifications induced by cadmium and arsenic during breast and prostate cancer development.** *Environmental Research* 2019, 178: 108700, <https://doi.org/10.1016/j.envres.2019.108700>. **IF = 5.026**
29. Asavei T, Bobeica M, Nastasa V, Manda G, et al. **Laser-driven radiation: Biomarkers for molecular imaging of high dose-rate effects.** *Medical Physics* 2019, 46(10): e726-e734. **IF = 2.617**
30. Robledinos-Anton N, Fernandez-Gines R, Manda G, Cuadrado A. **Activators and inhibitors of NRF2: A review of their potential for clinical development.** *Oxid Med Cell Longev* 2019, 2019:9372182. **IF = 4.868**
31. Radu Albuлесcu, Adrian-Claudiu Popa, Ana-Maria Enciu, Lucian Albuлесcu, Maria Dudau, Ionela Daniela Popescu, Simona Mihai, Elena Codrici, Sevinci Pop, Andreea-Roxana Lupu, George E Stan, Gina Manda, Cristiana Tanase. **Comprehensive In Vitro Testing of Calcium Phosphate-Based Bioceramics with Orthopedic and Dentistry Applications.** *Materials* 2019, 12(22): 3704. **IF = 2.972**
32. Natalia Radulea, Rica Boscencu, Radu Socoteanu, Gina Manda, Ionela Victoria Neagoe. **The Effect of Some Amphiphilic Porphyrins on the Transmembrane Potential of Cultured L929 Cells.** *Revista de Chimie* 2019, 70(4): 1288-1292. **IF = 1.605**
33. Gina Manda, Mihail Eugen Hinescu, Ionela Victoria Neagoe, Luis Filipe Vieira Ferreira, Rica Boscencu, Paul Vasos, Selma Huveyda Basaga, Antonio Cuadrado. **Emerging Therapeutic Targets in Oncologic Photodynamic Therapy.** *Current Pharmaceutical Design* 2019, 24(44): 5268-5295. **IF=2.962**
34. Panait ME, Chilug L, Negoita V, Busca A, Manda G, Niculae D, Dumitru M, Gruia MI. **Biological effects induced by ^{68}Ga - conjugated peptides in human and rodent tumor cell lines.** *Molecular Imaging and Biology* 2018, 25: 979–987. **IF=3.466**

35. Boscencu R, Socoteanu RP, Manda G et al. **New A3B porphyrins as potential candidates for theranostic. Synthesis and photochemical behaviour.** *Dyes and Pigments* 2018, 160: 410-417. **IF=3.767**
36. Codeanu C, Popescu CC, Mogosan C, Enache L, Manda G, Berghea F, Groseanu L, Predeteanu D. **Targeting interleukin 17 in the treatment of rheumatoid arthritis.** *Farmacia* 2018, 66(3): 390-398. **IF=1.507**
37. Antonio Cuadrado, Gina Manda, Ahmed Hassan, et al. **Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach.** *Pharmacological Reviews* 2018, 70(2):348-383. **IF=17.17**
38. Pietro Ghezzi, Luciano Floridi, Diana Boraschi, Antonio Cuadrado, Gina Manda, Snezana Levic, Fulvio D'Acquisto, Alice Hamilton, Toby J Athersuch, Liza Selley. **Oxidative stress and inflammation induced by environmental and psychological stressors: A biomarker perspective,** *Antioxidants & redox signaling* 2018, 28(9): 852-872. **IF= 6.337**
39. Burns JS, Manda G. **Metabolic Pathways of the Warburg Effect in Health and Disease: Perspectives of Choice, Chain or Chance,** *International Journal of Molecular Science* 2017, 18(12):2755. **IF=3.482**
40. Rica Boscencu, Gina Manda, Natalia Radulea, Radu Petre Socoteanu, Laura Cristina Ceafalan, Ionela Victoria Neagoe, Isabel Ferreira Machado, Selma Huveyda Basaga, Luís Filipe Vieira Ferreira. **Studies on the Synthesis, Photophysical and Biological Evaluation of Some Unsymmetrical Meso-Tetrasubstituted Phenyl Porphyrins,** *Molecules* 2017, 22(11): 1815. **IF=2.988**
41. Chilug LE, Leonte RA, Barbinte Patrascu ME, Ion AC, Tuta CS, Raicu A, Manda G, Niculae D. **In vitro binding kinetics study of gold nanoparticles functionalized with 68Ga-DOTA conjugated peptides.** *J Radioanal Nucl Chem* 2017, 3(2):1485-1493. **IF = 1.282**
42. Barca M, Manda G, Ciobanu AM, Balalau C, Lupuleasa D, Traian G, Dragomiroiu GTAB, Pop A, Popa DE, Baconi DL. **Immunomodulatory effects of methadone following methotrexate therapy in a rat model of arthritis,** *Farmacia* 2017, 65(3):423-428. **IF = 1.348**
43. Asavei T, Tomut M, Bobeica M, Aogaki S, Cernaianu MO, Ganciu M, Kara S, Manda G, et al. **Materials in extreme environments for energy, accelerators and space applications at ELI-NP,** *Romanian Reports in Physics* 2016, 68(Suppl): S275–S347. **IF = 1.367**
44. Checheriță IA, Manda G, Hinescu ME, Peride I, Niculae A, Bilha S, Gramaticu A, Voroneanu L, Covic A. **New molecular insights in diabetic nephropathy.** *International Urology and Nephrology* 2016, 48(3): 373-387. **IF = 1.292**
45. Dumitrache F, Morjan IG, Fleaca CI, Badoi A, Manda G, Pop S, Marta DS, et.al. **Highly magnetic Fe2O3 nanoparticles synthesized by laser pyrolysis used for biological and heat transfer applications.** *Applied Surface Science* 2015, 336: 297–303. **IF = 2.711**
46. Socoteanu R, Manda G, Boscencu R, Vasiliu G, Anabela Sousa Oliveira. **Synthesis, spectral analysis and preliminary in vitro evaluation of some tetrapyrrolic complexes with 3d metal ions.** *Molecules* 2015, 20(9): 15488-15499, doi:10.3390/molecules200915488. **IF = 2.465**
47. Manda G, Isvoranu G, Comanescu MV, Manea A, Debeleac Butuner B, Korkmaz KS. **The redox biology network in cancer pathophysiology and therapeutics.** *Redox Biology* 2015, 5: 347-357. **IF = 6.235**
48. Manea SA, Constantin A, Manda G, Sasson S, Manea A. **Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms.** *Redox Biology* 2015, 5: 358-366. **IF = 6.235**
49. Manda G, Mocanu MA, Marin DE, Taranu I. **Dual Effects Exerted in Vitro by Micromolar Concentrations of Deoxyribose on Undifferentiated Caco-2 Cells.** *Toxins* 2015, 7(2), 593-603. **IF = 3.571**
50. Manda G, Checherita AI, Comanescu MV, Hinescu ME. **Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes.** *Mediators of Inflammation* 2015, 2015, Article ID 604208. **IF = 3.418**
51. Margina D, Ilie M, Manda G, Neagoe I, Danciulescu-Miulescu R, Purdel CD, Gradinaru D. **In vitro effects of prolonged exposure to quercetin and epigallocatechin gallate of the**

- peripheral blood mononuclear cell membrane.** *Cellular and Molecular Biology Letters* 2014, 19: 542-560. **IF = 1.782**
52. Margina D, Gradinaru D, Manda G, Neagoe I, Ilie M. **Membranar effects exerted in vitro by polyphenols – quercetin, epigallocatechin gallate and curcumin – on HUVEC and Jurkat cells, relevant for diabetes mellitus.** *Food Chem Toxicol*, 61:86-93, 2013, pii: S0278-6915(13)00155-5. **IF = 2.610**
53. Nechifor MT, Niculițe CM, Urs AO, Regalia T, Mocanu M, Popescu A, Manda G, Dinu D, Leabu M. **UVA Irradiation of Dysplastic Keratinocytes: Oxidative Damage versus Antioxidant Defense.** *Int. J. Mol. Sci*, 13, 16718-16736, 2012. **IF = 2.464**
54. Marin DE, Taranu I, Burlacu R, Manda G, Motiu M, Neagoe I, Dragomir C, Stancu M, Calin L. **Effects of zearalenone and its derivatives on porcine immune response.** *Toxicology In Vitro*. 25(8):1981-1988, 2011. **IF = 2.775**
55. Taranu I, Daniela E. Marin DE, Manda G, Motiu M, Ionela Neagoe I, Cristina Tabuc C, Stancu M, Olteanu M. **Assessment of the potential of a boron–fructose additive in counteracting the toxic effect of *Fusarium* mycotoxins.** *Br J Nutrition*, 106(3): 398-407, 2011. **IF = 3.013**
56. Rica Boscencu, Mihaela Ilie, Radu Socoteanu, Anabela Sousa Oliveira, Carolina Constantin, Monica Neagu, Gina Manda, Luis Filipe Vieira Ferreira. **Synthesis, Basic Spectral and Biological Evaluation of Some Copper (II) Mesoporphyrinic Complexes.** *Molecules*, 15(5), 3731-3743, 2010. **IF = 1.988**
57. Lidia Matei, Ionela Neagoe, C. Postolache, C.V. Tanase, G. Bubueanu, Gina Manda. **In vitro and in vivo Radiometrical Studies For Evaluation of New Nucleoside Analogue Behavior.** *J. Label Compd. Radiopharm.* 53: 294-299, 2010. **IF = 1.096**
58. Gina Manda, Marina Tamara Nechifor, Teodora-Monica Neagu. **Reactive Oxygen Species, Cancer and Anti-Cancer Therapies.** *Current Chemical Biology*, 3(1): 342-366, 2009.
59. Gina Manda, Monica Neagu, Carolina Constantin, Ionela Neagoe, Catalin Codreanu. **Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one-month therapy with leflunomide.** *Rheumathology International*, 29(8): 937-946, 2009. **IF = 1.493**

LIST OF PATENTS

- OSIM patent 131946/2019** Tetrapyrrolic compound with theranostic applications and obtaining process – authors: Boscencu R, Manda G, Socoteanu RP, Hinescu ME, Radulea N, Neagoe I, Ferreira LFV.
- OSIM patent 01030/2017** Porphyrin derivative for theranostic use – authors: Boscencu R, Manda G, Socoteanu RP, Hinescu ME, Neagoe I, Olariu L, Dumitriu B.
- OSIM patent 125018 B1/2015** Biofunctionalized porphyrinic compound – authors: Socoteanu R, Boscencu R, Nacea V, Constantin C, Manda G, Neagu M, Ilie M, Oliveira AS, Ferreira LFV, published in RO-BOPI 4/30.04.2015
- OSIM patent 126761 B1/2014** Asymmetrically substituted porphyrinic compound, as a photosensitizing agent, used in cancer diagnosis and its preparation process – authors: Boscencu R, Socoteanu R, Constantin C, Neagu M, Manda G, Ilie M, Nacea V, Gird CE, Oliveira AS, Ferreira LFV.
- OSIM patent 128433 A2/2013** Procedure for the identification and dosing by HPLC of leflunomide in the patients' blood – authors: Negrei C, Baconi D, Margină D, Bălănescu A, Berghea F, Ilie M, Manda G, published in RO-BOPI 5/30.05.2013
- OSIM patent 123419 B1/2012** Asymmetrically substituted tetrapyrrolic compound, obtaining process and biological evaluation at cellular level – authors: Boscencu R, Socoteanu R, Nacea V, Constantin C, Manda G, Neagu M, Ilie M, Baconi DL, Oliveira AS, Ferreira LFV, published in RO-BOPI 3/30.03.2012

LIST OF SELECTED RESEARCH PROJECTS

| Project/Research Program | Function | Duration |
|---|--|-----------|
| International projects | | |
| EURAMET / 21GRD02 BIOSPHERE Metrology for Earth Biosphere: Cosmic rays, ultraviolet radiation and fragility of ozone shield, coordinator Faton Krasniqi, Physikalisch-Technische Bundesanstalt, Braunschwig, Germany, 22 European institutions involved, WP4 member and task coordinator, | WP4 coordinator of Task 4.2 | 2022-2025 |
| AO-2017-IBER (ESA-HRE-UL-LE-0003) Redox signalling and the transcription factor NRF2 as therapeutic target for counteracting the deleterious effects of spaceflight environment, financed by ESA through the AO-IBER program. Partner: GSI Center for Heavy Ion Research, Germany | Scientific coordinator | 2017-2021 |
| POC P37_732, contract 29/2016 Knowledge transfer in redox biology for developing advanced molecular tools in neurodegenerative diseases - focus on the signature of Nrf2 transcription factor in diagnosis and therapy, coordinated by Prof. Antonio Cuadrado (Autonomous University of Madrid, Spain) | Coordinator of cellular studies and representative of the project director in Ronaia | 2016-2020 |
| M-Era.NET (contract 52/2014) Advanced theranostic approach in cancer combining photodynamic therapy and nanoparticles – NANOTHER, coordinated by Prof. Luis Filipe Vieira Ferreira (Lisbon University, Portugal) | Leader of WP5 Preclinical study | 2016-2019 |
| COST Action CA15107 Multi-Functional Nano-Carbon Composite Materials Network-MultiComp, coordinated by Dr. Sharali MALIK (Karlsruhe Institute of Technology, Institute of Nanotechnology) | Vice-leader of WG3-Characterization, Health, Safety and Environment | 2015-2019 |
| COST Action BM1203 EU-ROS coordinated by Prof. Andreas DAIBER (University Medical Center Mainz, Germany) | Member of the management team | 2012-2016 |
| MNT-ERA NET (Ref 419) Tetrapyrrole nanostructures towards fluorescent molecular markers for biomedicine. Cooperation with Portugal (Instituto Superior Técnico – Technical University of Lisbon – Centro de Química-Física Molecular e Instituto de Nanociência e Nanotecnologia) | Investigator | 2010-2012 |
| Bilateral Cooperation Program Greece-Romania, nr. 7285/02 “Victor Babes” National Institute of Pathology, Romania, and National & Kapodistrian University of Athens, Greece Immunomodulating potential of prothymosin alpha and its fragments on lymphocyte functions in vitro. Analysis of the mechanisms of action of the polypeptide and specific peptides spanning its primary structure, coordinated by Dr. Ourania Tsitsilonis (Kapodistrian University of Athens, Greece) | Investigator | 2003-2005 |
| Clinical trial LOR/VIR/PO3/002 –Lorus Company, Canada Clinical Trial phase III, double blind, multicenter, randomized study in chemo-naive patients with locally advanced or metastatic pancreatic | Investigator | 2003-2005 |

| | | |
|---|---|-----------|
| cancer to compare a combination therapy of Virulizin® plus Gemcitabine versus placebo plus Gemcitabine; optional second-line therapy may include continuation of Virulizin® or placebo, alone or in combination with 5-Fluorouracil | | |
| COST Actions | | |
| COST / COST Action CA20121 Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases | Vice-chair Scientific Representative of the Grant Holder | 2021-2025 |
| COST / COST Action CA19114 Network for Optimized Astatine labeled Radiopharmaceuticals | Member | 2020-2024 |
| COST / COST Action CA15107 Multi-Functional Nano-Carbon Composite Materials Network-MultiComp, coordinated by Dr. Sharali MALIK (Karlsruhe Institute of Technology, Institute of Nanotechnology) | Vice-leader of WG3- Characterization, Health, Safety and Environment | 2015-2019 |
| COST / COST Action BM1203 EU-ROS coordinated by Prof. Andreas DAIBER (University Medical Center Mainz, Germany) | Member of the management team | 2012-2016 |
| European Social Fund "Human Resources" | | |
| POSDRU/81/3.2/S/59497 Vocational and organizational training for immunological laboratory employees by implementing high tech and quality management-IMUNOLAB. Coordinator Prof. Victor Cristea; cooperation with the University of Goteborg | Teaching coordinator | 2010-2013 |
| POSDRU 81/3.2/S/58819 Professional formation system of the medical personnel in the field of new technologies applicable in the health system-TDM; coordinator Acad. Laurentiu M. Popescu | Partnership manager | 2010-2013 |
| POSDRU/89/1.5/S/141531 Development of human resources – PhD students and postdoctoral researchers-DPD (Dezvoltarea resurselor umane - doctoranzi si postdoctoranzi - pentru cercetare de excelenta in domeniile sanatare si biotehnologii-DPD), coordinator Acad. Laurentiu M. Popescu | Tutor | 2014-2015 |
| POSDRU/159/1.5/S/135760 Career profile: Romanian Researcher - CERO (Profil de Carieră: Cercetător Român - CERO); coordinator: Conf. Dr. Ismail Gener | Tutor | 2014-2015 |
| National projects | | |
| PN 23.16.02.01/2023 Stress genes as therapeutic targets in the radiotherapy and photodynamic therapy of colon carcinoma | Coordinator | 2023-2026 |
| PED / 637PED/2022 Customized photodynamic protocol with innovative porphyrins and redox modulators in premalignant cutaneous disorders - preclinical demonstration | Coordinator | 2022-2024 |
| ELI-RO / ELI-09 /2020 Advanced biological methods for investigating stress responses of normal and pre-leukemic cells under irradiation at ELI-NP – applications for astrobiology and FLASH radiotherapy (CELLI) | Coordinator | 2020-2023 |
| PN 19.29.02.02 A systems biology approach for developing new redox therapies for increasing the radiotherapy efficacy | Project coordinator | 2019-2022 |

| | | |
|--|------------------------------------|-----------|
| PCCDI 35 /2018 Genomic mapping of population from areas contaminated with radioisotopes and heavy metals aiming to increase national security (ARTEMIS) | Component project 3 coordinator | 2018-2021 |
| PCCDI 64/2018 Development of radiopharmaceuticals and nuclear techniques in oncology, for imagistic diagnosis and personalized treatment at molecular level (ONCORAD) | Component project 3 coordinator | 2018-2021 |
| PN 18.21.01.02 / 2018 Molecular signature of the transcription factor NRF2 – new therapeutic approaches for increasing radiotherapy efficacy in cancer | Project coordinator | 2018 |
| ELI-RO 13-ELI/2016 Development of the national technological platform for investigating the interaction of complex biological systems with space radiations in the context of ELI-NP / ABEL (ASTRO-BIO-ELI) | Scientific coordinator | 2016-2019 |
| RO-CERN E05/2014 Advanced technologic platform for preclinical studies on radiopharmaceuticals | Scientific coordinator | 2014-2016 |
| PN 16.22.03.03 Molecular networks connecting NLRP3 inflammasome and redox signaling in rheumatoid arthritis | Project coordinator | 2016-2017 |
| PN 09.33.02.07 TNF-alfa, TGF-beta, VEGF and EGFR - new biomarkers in molecular therapies in rheumatoid arthritis | Project coordinator | 2013-2015 |
| PNCIDI2 CEEX 61-018/2007 Novel nucleoside analogs potentially active in cancer therapy – from synthesis to cellular and molecular targets | Project coordinator | 2007-2010 |
| Viasan 229/2003 Immunomodulatory signals delivered <i>in vitro</i> by opioid receptors in rheumatoid arthritis | Project coordinator | 2003-2005 |
| Viasan 091/2001 Dynamic of functional cellular and molecular parameters of rheumatoid arthritis patients treated with inhibitors of nucleotide synthesis (leflunomide and methotrexate) | Project coordinator | 2001-2004 |
| CALIST 1087/ 2004 System of cellular immunology methods: validation and applications in toxicology and pharmacology | Project coordinator | 2004-2006 |
| PCCA 124/2014 The Th17 network - predictor of response to anti-TNF α therapy in rheumatoid arthritis | Partner co-director | 2014-2016 |
| PNCIDI2 102/2012 Impact of feed co-contamination and mitigating solutions to increase feed safety, animal health and food quality | Partner co-director | 2012-2015 |
| PNCIDI2 42-152/2008 New biological research and methods to assess early toxicity of immunosuppressant therapy in rheumatic diseases | Partner co-director | 2008-2011 |
| PNCIDI2 52-122/2008 Security and quality of feeding stuffs and animal products by nutritional solutions for diminishing negative effects of mycotoxins, natural contaminants of farm animals and humans | Partner co-director | 2008-2011 |
| PNCIDI2 61-037/2008 Development of a QSAR system for modeling the activity of anti-tumor and anti-rheumatic therapeutic agents in individualized therapies | Partner co-director | 2007-2010 |
| CEEX 36/2005 Radioactive compounds in molecular biology, pharmacology, and toxicology | Partner co-director | 2005-2008 |
| CEEX 27/2005 Psychosomatic changes in drug-addicts during substitution therapy | Partner co-director | 2005-2008 |

| | | |
|--|---------------------|-----------|
| CEEX 25/2005 Mycotoxins produced by Fusarium fungi and the food chain – new methods to characterize and prevent toxicity | Partner co-director | 2005-2008 |
| Biotech 378/2003 Modulation of apoptosis with biologically active substances in relation to oxidative stress and membrane processes | Partner co-director | 2003-2005 |
| Biotech 4745/2004 Studies regarding the signal transduction mechanisms of physiological cellular receptors: modulation with natural biologically active substances with therapeutic potential | Partner co-director | 2003-2005 |